Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Composition containing tenuifoliside and ginsenoside

A technology of ginsenosides and polygala sugar esters, which is applied to the composition of polygala sugar esters and ginsenosides to prepare drugs for the treatment and improvement of depression. It can solve the problems of slow onset of action, adverse reactions, and easy recurrence, and achieve enhanced toxicity, The effect of shortening the immobility time of forced swimming

Inactive Publication Date: 2015-08-19
ZHEJIANG UNIV
View PDF1 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] Antidepressant chemical drugs have a series of problems, such as slow onset, easy relapse and many adverse reactions, etc.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composition containing tenuifoliside and ginsenoside
  • Composition containing tenuifoliside and ginsenoside

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0011] Example 1 : the preparation method of polygala sugar ester and ginsenoside of the present invention

[0012] (1) The effective part of polygala sugar esters used in the present invention can be obtained by referring to the method disclosed in Patent No. 201410215399.5: using polygala medicinal material as raw material, using ethanol solution reflux method to extract, specifically: 70% ethanol with 10 times the quality of polygala medicinal material The solution was used as the extraction solvent, refluxed and extracted 3 times, each time for 1.5 h, the combined extracts were concentrated under reduced pressure until no alcohol smell (60 ℃), and the Polygala extract was obtained. The obtained Polygala extract was purified by D130 macroporous resin. The concentration of the sample solution is 0.25 g / ml containing crude drug, the sample loading speed is 2 Bv / h, and the sample volume is 4 Bv; in the elution process, it is first washed with 5 Bv of water, and the water was...

Embodiment 2

[0014] Example 2 : the maximum tolerated dose experiment of the composition of the present invention

[0015] (1) Materials and methods

[0016] Polygala sugar esters and ginsenosides were obtained by referring to the method in Example 1, and were prepared as a suspension with 0.5% sodium carboxymethylcellulose. Before use, the polygala sugar ester: ginsenoside weight ratios are respectively 0.5:0.5 and 0.11:0.89, and mixed to form a composition.

[0017] The maximum concentration and maximum administration volume of 0.4 mL / 10 g / time gavage was administered twice a day with an interval of 6 hours. The body weight and various symptoms of the mice were observed on the day of administration and within the following two weeks.

[0018] (2) Results:

[0019] On the day and the next day after intragastric administration of the mice, no death occurred in all the administration groups, and no apparent adverse symptoms were observed in the following two weeks. There was no apparen...

Embodiment 3

[0022] Example 3 : Mouse Yohimbine Toxicity Enhancement Experiment

[0023] (1) Materials and methods:

[0024] Polygala sugar esters and ginsenosides were obtained by referring to the method in Example 1, according to the weight ratio of polygala sugar esters: ginsenosides 0.11:0.89.

[0025] Yohimbine Hydrochloride: Aladdin Chemistry Co., Ltd. Batch No.: 29107. Normal saline: Hangzhou Jiutian Animal Health Products Co., Ltd. Batch number: 2014071901.

[0026] Male ICR mice, clean grade, weighing 18-24 g, were given standard pelleted feed and pure drinking water during the feeding period. Set solvent control group, fluoxetine positive drug control group (20 and 40 mg / kg), polygala sugar ester group (2.5, 5 and 10 mg / kg), ginsenoside group (20, 40 and 80 mg / kg), Polygala sugar ester and ginsenoside composition group (11.25 and 22.5 mg / kg), administered by intraperitoneal injection. After administration of the test drug or solvent, a sublethal dose of yohimbine (25 mg / kg)...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a composition containing tenuifoliside and ginsenoside. The composition is formed by tenuifoliside and ginsenoside in a weight ratio in a range of 0.5:0.5 to 0.11:0.89. Single effective tenuifoliside and ginsenoside are extracted from tenuifoliside and ginsenoside medicine materials, and both reach more than 50%. The composition can be applied to preparation of medicine for treating and improving depression. Two effective parts are combined, and accordingly, the mouse yohimbine toxicity is enhanced apparently, and the mouse forced swimming unmovable time is shortened apparently. By combining the two effective parts, the effect is enhanced compared with the effect of single use of any one part. By means of the composition, medicine definitive in curative effect and slight in adverse reaction is provided for treating and improving depression.

Description

technical field [0001] The invention belongs to natural medicine composition, and in particular relates to the composition of polygala sugar ester and ginsenoside and its application in preparing medicine for treating and improving depression. Background technique [0002] Depression, also known as depressive disorder, is the main type of mood disorder with significant and persistent low mood as the main clinical feature. According to the statistics of the World Health Organization, the incidence of depression in the world is about 53.1%, while in developed countries it is close to 60%. 100 million. Among the adult population over the age of 18, the number of patients with depression is increasing at a rate of 41.3% per year. The situation of depression in our country is not optimistic. At present, the incidence of depression in our country is about 24%. According to epidemiological survey data in some areas, the prevalence of depression is about 29-35%, which is similar t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K36/69A61P25/24
Inventor 栾连军施琦渊吴永江刘雪松
Owner ZHEJIANG UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com